Benitec Biopharma is a clinical-stage biotech focused entirely on developing BB-301, a single gene therapy candidate for Oculopharyngeal Muscular Dystrophy (OPMD), a rare inherited muscle disorder that causes progressive swallowing difficulties and eyelid drooping and currently has no approved treatments. BB-301 uses Benitec's proprietary "silence and replace" approach, delivered via a single AAV9 injection directly into the pharyngeal muscles. The construct simultaneously silences the mutant PABPN1 gene driving the disease and replaces it with a functional wildtype version — aiming for a one-time, potentially permanent correction rather than chronic dosing. Benitec differentiates this approach from conventional RNAi drugs, which degrade and require repeat administration, and from traditional gene therapy, which can introduce a replacement gene but cannot silence the underlying mutant. Benitec has no approved products, no revenue, and no commercial infrastructure. The company is currently enrolling patients in a Phase 1b/2a trial in the U.S. The long-term model is to advance BB-301 through trials and either commercialize independently, partner with larger pharma, or license the drug. Benitec also holds a broader ddRNAi technology platform it could out-license for other indications. BB-301 holds Orphan Drug Designation in both the U.S. and EU, which would confer seven and ten years of market exclusivity, respectively, upon approval. Benitec has 19 full-time employees, the majority in R&D, and funds operations through equity raises.